Core Viewpoint - The company has announced the use of temporarily idle raised funds for cash management, ensuring that it does not affect the normal operation of fundraising investment projects [1][4][5]. Summary by Sections 1. Basic Information on Raised Funds - The company raised a total of RMB 284.61 million through a simplified procedure for issuing shares, with a net amount of RMB 280.61 million after deducting related issuance costs [1][2]. 2. Investment Project Situation - The raised funds will be allocated to projects with a total investment of RMB 422.43 million, with RMB 284.61 million planned for use from the raised funds [2]. 3. Cash Management of Idle Funds - The company plans to use up to RMB 150 million of temporarily idle raised funds for cash management, with a usage period of up to 12 months from the board's approval date [3][4]. - The investment products will include safe and liquid options such as agreement deposits, structured deposits, and large certificates of deposit [3][5]. 4. Impact on Company Operations - The cash management of temporarily idle funds will not affect the company's daily operations or the normal progress of fundraising projects, and it aims to enhance the efficiency of fund utilization [4][5]. 5. Review Procedures - The board and supervisory committee approved the cash management proposal on May 29, 2025, without needing to submit it to the shareholders' meeting [6]. 6. Opinions from Supervisory Committee and Sponsor - The supervisory committee unanimously agreed that the cash management of idle funds would improve fund utilization efficiency without harming shareholder interests [5][6]. - The sponsor confirmed that the proposal complies with relevant regulations and will not affect the normal implementation of fundraising projects [5][6].

Core Viewpoint - The company, Aibo Medical, has approved the use of raised funds to replace self-raised funds that were previously invested in projects and paid issuance expenses, totaling RMB 40,556,134.86 [1][2] Fundraising Overview - Aibo Medical issued 3,593,615 shares at a price of RMB 79.20 per share, raising a total of RMB 284,614,308.00 in 2024 [1] - The net amount raised after deducting related issuance expenses is less than the intended investment amount, allowing the company to use self-raised funds for initial investments [1] Investment Project Details - The total investment amount for the projects is RMB 422,430,700, with RMB 284,614,308 intended to be funded by the raised funds [1] - The company has pre-invested self-raised funds in the projects, with specific amounts detailed for each project [1] Approval Process - The board of directors and the supervisory board approved the proposal on May 29, 2025, confirming compliance with regulations regarding the replacement of funds within six months of the funds being received [1][2] Opinions from Supervisory Board and Auditors - The supervisory board agrees that the replacement of self-raised funds aligns with the company's interests and complies with relevant laws and regulations [2] - The auditing firm, Xinyong Zhonghe, confirmed that the management's report accurately reflects the situation regarding the use of self-raised funds [2]

Core Points - The company is reviewing the qualifications of independent director candidates for its third board of directors [1][2] - The nominated candidates, Wang Jing, Li Xunhu, and Wang Dongsheng, do not hold shares in the company and have no significant relationships with major stakeholders [1] - The candidates meet all legal and regulatory requirements for independent directors, including no disqualifications or penalties from regulatory bodies [1][2] Summary by Sections - **Candidate Qualifications** - The independent director candidates possess extensive professional knowledge and are familiar with relevant laws and regulations [2] - Their educational background, work experience, and business capabilities align with the company's requirements for independent directors [2] - **Nomination Process** - The nomination committee agrees to propose Wang Jing, Li Xunhu, and Wang Dongsheng as candidates for the third board of directors [2] - The proposal will be submitted for review at the company's 19th meeting of the second board of directors [2]

Meeting Information - The annual shareholder meeting of Aibo Medical is scheduled for June 19, 2025 [1] - The meeting will be held at the company's headquarters in Beijing [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's voting system [1] Voting Procedures - Shareholders can vote from June 19, 2025, during specified trading hours [1] - The voting process includes provisions for margin trading and other related accounts [1] - Shareholders must complete identity verification to vote online [1][2] Agenda Items - The meeting will discuss several proposals, including the establishment of internal control systems and the election of the third board of directors [1] - Non-cumulative voting will be used for certain proposals, while cumulative voting will be applied for the election of directors [1][5] Attendance Requirements - Only shareholders registered by the close of trading on June 13, 2025, are eligible to attend [3] - Proxy representation is allowed, and specific documentation is required for registration [3][4] Registration Details - Registration for the meeting will take place on June 18, 2025, at the company's office [3] - Shareholders must provide necessary identification and documentation for registration [3][4] Additional Information - The company will provide a reminder service for shareholders to ensure participation [1] - Contact information for inquiries regarding the meeting is provided [6]

证券代码：688050 证券简称：爱博医疗 公告编号：2025-034 爱博诺德（北京）医疗科技股份有限公司 关于使用募集资金向控股子公司提供借款以实施募投 项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第二届董事会第十九次会议和第二届监事会第十六次会议，审议通过 《关于公司使用募集资金向控股子公司提供借款以实施募投项目的议案》，同意 公司使用募集资金向控股子公司江苏天眼医药科技股份有限公司（以下简称"天 眼医药"）提供不超过 26,000.00 万元的借款以实施募投项目。公司监事会对本事 项发表了明确的同意意见，保荐机构中国银河证券股份有限公司（以下简称"保 荐机构"）对本事项出具了明确的核查意见。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意爱博诺德（北京）医疗科技 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号）， 公司 2024 年度以简易程序向特 ...

Board Restructuring Announcement - The company is undergoing a board restructuring as the term of the second board is about to expire, in accordance with relevant laws and regulations [1][2] - The company will hold its annual general meeting in 2024 to vote on the new board members, with both non-independent and independent directors elected through a cumulative voting system [2][3] Board Candidates - The company has nominated several candidates for the third board, including non-independent directors: Xie Jiangbing, Wang Zhao, Jia Baoshan, Chen Yong, and Zhang Jian [1][2] - Independent director candidates include Wang Jing, Li Xunhu, and Wang Dongsheng, with Wang Jing being a professional accountant [1][2] Candidate Qualifications - All nominated candidates meet the qualifications required by laws and regulations, with no disqualifications under the Company Law or other relevant guidelines [2][4] - The candidates have no prior administrative penalties or disqualifications from the China Securities Regulatory Commission or stock exchanges [2][4] Current Board Performance - The current board has been diligent and has contributed positively to the company's sustainable development during their tenure [3]

独立董事提名人声明与承诺 爱博诺德（北京）医疗科技股份有限公司 提名人爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）董事会， 现提名王静女士为公司第三届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部简直、有无重大失信等不良记录等情况。被提 名人已书面同意出任公司第三届董事会独立董事候选人（参见该独立董事候选人声 明）。 提名人认为，被提名人具备独立董事任职资格，与公司之间不存在任何影响其 独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规章 及其他规范性文件，具有五年以上法律、经济、会计、财务、管理或者其他履行独 立董事职责所必需的工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规章以及公司规章的要 求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监管 规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管 ...

Core Viewpoint - The company announced a cash dividend distribution plan for the fiscal year 2024, proposing a cash dividend of 3.50 RMB per 10 shares, which reflects a cautious approach to balancing shareholder returns and the need for reinvestment in growth initiatives [1][2][4]. Profit Distribution Plan - The total cash dividend amount is 87,591,975.59 RMB, representing 22.55% of the net profit attributable to shareholders for 2024, which is 388,402,949.75 RMB [2][4]. - The cash dividend will be based on the total share capital minus shares held in the company's repurchase account, with adjustments made if the total share capital changes before the record date [1][2]. Company Financials - As of December 31, 2024, the company's available distributable profits are 997,112,310.53 RMB for the parent company and 949,502,012.53 RMB for the consolidated financial statements [1][4]. - The company has experienced continuous high growth in revenue and net profit over the past three years, indicating a stable financial condition [5]. Industry Context and Company Strategy - The company operates in the ophthalmic medical device manufacturing sector, focusing on cataract surgery, myopia prevention, and vision care, with a strong position in artificial lenses and orthokeratology lenses [4][5]. - The industry is currently undergoing product upgrades, and the company is expanding its production capacity and market presence, particularly in the contact lens segment [4][5]. Future Plans and Investment - The company plans to retain undistributed profits for expanding production, increasing R&D investment, and exploring new growth points, which is essential for its long-term strategic development [5][6]. - The board of directors has carefully evaluated the profit distribution plan, ensuring it aligns with the company's growth needs and shareholder return expectations [6][7].

证券代码：688050 证券简称：爱博医疗 公告编号：2025-029 爱博诺德（北京）医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届监事 会第十六次会议通知及相关材料于 2025 年 5 月 23 日以电子邮件的方式发出。会 议于 2025 年 5 月 29 日在公司会议室以现场与通讯相结合方式召开，本次会议由 监事会主席王丹璇女士召集并主持，应出席的监事 3 人，实际出席的监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、 规章、规范性文件和《公司章程》等有关规定，会议形成的决议合法、有效。经 与会监事认真讨论，审议通过如下事项： 一、审议并通过《关于 2024 年年度利润分配方案的议案》 经与会监事认真审议，监事会认为：公司 2024 年年度利润分配方案充分考虑 了公司盈利情况、现金流状态及资金需求计划，结合了当前发展阶段、长远发展 规则及股东合理回报规划等各种 ...

爱博诺德（北京）医疗科技股份有限公司监事会 关于公司 2021 年限制性股票激励计划首次授予部分第四个归属 期及预留授予部分第三个归属期归属名单的核查意见 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）监事会依据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办 法》"）、 创板上市公司自律监管指南第 4 号——股权激励信息披露》等法律、法规及规范 性文件及《爱博诺德（北京）医疗科技股份有限公司章程》 （以下简称"《公司章 程》"）的有关规定，对公司《2021 年限制性股票激励计划》（以下简称"《激励 计划》"）首次授予限制性股票第四个归属期及预留授予限制性股票第三个归属期 归属名单进行了核查，发表核查意见如下： 监事会认为，首次授予 71 名激励对象及预留授予 6 名激励对象符合《公司 法》《证券法》等法律、法规、规范性文件以及《公司章程》规定的任职资格， 符合《管理办法》《上市规则》等法律、法规和规范性文件规定的激励对象条件， 符合公司《2021 年限制性股票激励计划》及其摘要规定的激励对象 ...